Terms: = Liver cancer AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Prognosis
5358 results:
1. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract] [Full Text] [Related]
2. Tebentafusp in the treatment of metastatic uveal melanoma - the first patient treated in the Czech Republic.
Klabusay M; Bábková B
Klin Onkol; 2024; 38(2):134-138. PubMed ID: 38697822
[TBL] [Abstract] [Full Text] [Related]
3. Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: An open-label, prospective and single-centre phase II trial.
Zeng TM; Jiang TY; Yang G; Cheng Z; Lou C; Wei W; Tao CJ; Hu S; Wang H; Cui XW; Tan YX; Dong LW; Wang HY; Yuan ZG
Clin Transl Med; 2024 May; 14(5):e1675. PubMed ID: 38689424
[TBL] [Abstract] [Full Text] [Related]
4. Undifferentiated Embryonal Sarcoma of the liver with Epithelioid Features: A Case Report of an Exceptional Histological Heterogeneity among Rare Diseases.
Kersik A; Bracchetti G; Bonomi A; Bovo G; Serena Cuttin M; Germini A; Gjoni E; Granieri S; Cotsoglou C
Ann Ital Chir; 2024; 95(2):119-125. PubMed ID: 38684493
[TBL] [Abstract] [Full Text] [Related]
5. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
[TBL] [Abstract] [Full Text] [Related]
6. Paraneoplastic Syndromes in Hepatocellular Carcinoma, Epidemiology, and Survival: A Retrospective Seven Years Study.
Burciu C; Sirli R; Bende R; Vuletici D; Miutescu B; Moga T; Bende F; Popescu A; Sporea I; Koppandi O; Miutescu E; Iovanescu D; Danila M
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674198
[No Abstract] [Full Text] [Related]
7. A preliminary study of optimal treatment response rates in patients undergoing hepatic arterial infusion chemotherapy combined with molecular targeting and immunotherapy.
Li M; Liao J; Wang L; Lv T; Sun Q; Xu Y; Guo Z; Quan M; Qin H; Yu H; Zhang K; Xing W; Yu H
Front Immunol; 2024; 15():1303259. PubMed ID: 38660298
[TBL] [Abstract] [Full Text] [Related]
8. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma.
Zhu M; Jin M; Zhao X; Shen S; Chen Y; Xiao H; Wei G; He Q; Li B; Peng Z
BMC Med; 2024 Apr; 22(1):165. PubMed ID: 38637772
[TBL] [Abstract] [Full Text] [Related]
9. Ferroptosis-related lncRNA NRAV affects the prognosis of hepatocellular carcinoma via the miR-375-3P/SLC7A11 axis.
Zong K; Lin C; Luo K; Deng Y; Wang H; Hu J; Chen S; Li R
BMC Cancer; 2024 Apr; 24(1):496. PubMed ID: 38637761
[TBL] [Abstract] [Full Text] [Related]
10. Relationship of FDG PET/CT imaging features with tumor immune microenvironment and prognosis in colorectal cancer: a retrospective study.
Lee JW; Ahn H; Yoo ID; Hong SP; Baek MJ; Kang DH; Lee SM
Cancer Imaging; 2024 Apr; 24(1):53. PubMed ID: 38627864
[TBL] [Abstract] [Full Text] [Related]
11. Impact of hepatic inflammation and fibrosis on the recurrence and long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after hepatectomy.
Hao X; Xu L; Lan X; Li B; Cai H
BMC Cancer; 2024 Apr; 24(1):475. PubMed ID: 38622578
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy of radiofrequency ablation combined with sorafenib for treating liver cancer complicated with portal hypertension and prognostic factors.
Yang LM; Wang HJ; Li SL; Gan GH; Deng WW; Chang YS; Zhang LF
World J Gastroenterol; 2024 Mar; 30(11):1533-1544. PubMed ID: 38617449
[TBL] [Abstract] [Full Text] [Related]
13. Single cell glycan-linkages profiling for hepatocellular carcinoma early diagnosis using lanthanide encoded bacteriophage MS2 based ICP-MS.
Liang Y; Liu Z; Zuo D; Chen S; Chen J; Yan X; Liu P; Wang Q
Talanta; 2024 Jul; 274():126056. PubMed ID: 38599123
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract] [Full Text] [Related]
15. Assessment of the Clinical Value of Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma.
Chen X; Mohammed AF; Li C
Clin Appl Thromb Hemost; 2024; 30():10760296231221535. PubMed ID: 38591958
[TBL] [Abstract] [Full Text] [Related]
16. A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract cancers (BTC) at high risk for recurrence: PURITY study.
Niger M; Nichetti F; Fornaro L; Pircher C; Morano F; Palermo F; Rimassa L; Pressiani T; Berardi R; Gardini AC; Sperti E; Salvatore L; Melisi D; Bergamo F; Siena S; Mosconi S; Longarini R; Arcangeli G; Corallo S; Delliponti L; Tamberi S; Fea E; Brandi G; Rapposelli IG; Salati M; Baili P; Miceli R; Ljevar S; Cavallo I; Sottotetti E; Martinetti A; Busset MDD; Sposito C; Di Bartolomeo M; Pietrantonio F; de Braud F; Mazzaferro V
BMC Cancer; 2024 Apr; 24(1):436. PubMed ID: 38589856
[TBL] [Abstract] [Full Text] [Related]
17. Prediction of vessels encapsulating tumor clusters pattern and prognosis of hepatocellular carcinoma based on preoperative gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid magnetic resonance imaging.
Wang M; Cao L; Wang Y; Huang H; Cao S; Tian X; Lei J
J Gastrointest Surg; 2024 Apr; 28(4):442-450. PubMed ID: 38583894
[TBL] [Abstract] [Full Text] [Related]
18. [Effect of HBV DNA load on the safety and prognosis of systematic therapy in advanced hepatocellular carcinoma].
Zheng XR; Peng JX; Song X; Liu B; Zhong C; Chen XY; Zhang BX; Peng L; Zhu KS; Xie C
Zhonghua Yi Xue Za Zhi; 2024 Apr; 104(14):1160-1167. PubMed ID: 38583047
[No Abstract] [Full Text] [Related]
19. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.
Ohama H; Hiraoka A; Tada T; Hirooka M; Kariyama K; Hatanaka T; Tani J; Takaguchi K; Atsukawa M; Itobayashi E; Nishimura T; Tsuji K; Tajiri K; Ishikawa T; Yasuda S; Toyoda H; Fukunishi S; Ogawa C; Kakizaki S; Shimada N; Naganuma A; Kawata K; Kosaka H; Kuroda H; Matono T; Yata Y; Ochi H; Tada F; Nouso K; Morishita A; Itokawa N; Okubo T; Arai T; Tsutsui A; Nagano T; Yokohama K; Nishikawa H; Imai M; Koizumi Y; Nakamura S; Iijima H; Kaibori M; Hiasa Y; Kumada T;
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2042. PubMed ID: 38577725
[TBL] [Abstract] [Full Text] [Related]
20. Telomerase-related advances in hepatocellular carcinoma: A bibliometric and visual analysis.
Li HY; Zheng LL; Hu N; Wang ZH; Tao CC; Wang YR; Liu Y; Aizimuaji Z; Wang HW; Zheng RQ; Xiao T; Rong WQ
World J Gastroenterol; 2024 Mar; 30(9):1224-1236. PubMed ID: 38577190
[TBL] [Abstract] [Full Text] [Related]
[Next]
